Molecular 'rabble-rouser' fuels pancreatic cancer growth

May 10, 2018 by Kate Wighton, Imperial College London
Aggressive pancreatic cancer cells. Credit: Imperial College London

A type of molecular 'rabble-rouser' that triggers pancreatic cancer to become aggressive and spread around the body has been identified by scientists.

The team behind the early-stage research, led by Imperial College London and funded by Pancreatic Cancer UK, say the findings may open avenues for treatments that target these molecules.

The molecules, called microRNAs, could also potentially be used to assess how aggressive a patient's cancer is, and how likely it is to spread around the body.

Around 10,000 people are diagnosed with every year and the disease has the lowest survival of all the 20 common cancers, with less than seven per cent of patients surviving beyond five years.

In the latest research, published in the journal Nature Communications, scientists discovered that two microRNAs called miR-100 and miR-125b, work together with a molecule called Transforming Growth Factor Beta (TGF-b) to promote growth and spread of cancer.

MicroRNAs help control which genes are switched on and off in a cell. They have previously been implicated in cancer, as they can turn on genes that make cancerous.

Calming a cancer cell

By using the cutting-edge CRISPR techniques, the team generated cells lacking the part of the DNA required to produce these microRNAs.

Interestingly, the team showed that these cells, when no longer able to produce these microRNAs, switched back to a less aggressive behaviour. In addition, they showed TGF-b alone was no longer effective in driving tumour growth and spread. The team further validate these findings in mice models, where cells lacking these microRNAs injected into mice formed less tumours, and were less likely to spread to other areas of the body.

They then studied tumour samples from around 100 patients with pancreatic cancer and scanned these tumours for levels of the two microRNAs. The scientists found that aggressive tumours – which are more likely to prove fatal and spread around the body, contained higher levels of the microRNAs.

They then analysed patient survival, and found that patients with high levels of these molecules had worse survival rates.

Further experiments revealed these microRNAs affect a number of genes that trigger chaos in the cell, and lead to aggressive cancer. These genes are associated with uncontrolled cell growth, DNA damage and cell movement.

Test could reveal best treatment

Dr. Silvia Ottaviani, joint first author of the paper from the Department of Surgery and Cancer, explained: "These molecules act like the 'rabble-rousers' in tumour cells – they drive a number of processes that cause cancer cells to become aggressive, and more likely to invade other areas of the body. We see this when we look at the cells under a microscope – they become elongated and further apart from each other – they are spiky, angry, and they want to go everywhere in the body and cause trouble."

The team are now planning further investigations on these two microRNAs, added Dr. Ottaviani.

"We now need to find out if stopping the production of these molecules will slow pancreatic cancer growth, or make the easier to kill with chemotherapy. We are also looking at whether these molecules could one day form a type of test allowing doctors to gauge how aggressive a patient's cancer is, which would help them decide the best treatment options."

Reducing death rate

Dr. Ottaviani pointed out that most of the patient samples were obtained from pancreatic cancers that had spread to lymph nodes and nearby tissues and the team is now hoping to study more advanced and metastatic tumours in their next experiments.

Professor Justin Stebbing, joint first author from the Department of Surgery and Cancer at Imperial, added: "This groundbreaking work helps explain why some genes are turned on and off in , via new called long non-coding RNAs, and this will help in our understanding of how to eradicate them, increasing the cure rate and decreasing the death rate from ."

Explore further: Oestrogen causes neuroblastoma cells to mature into neurons

More information: Silvia Ottaviani et al. TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression, Nature Communications (2018). DOI: 10.1038/s41467-018-03962-x

Related Stories

Oestrogen causes neuroblastoma cells to mature into neurons

January 29, 2018
The female sex hormone oestrogen can perform an important role in neuroblastoma, a form of cancer mainly affecting young children. In laboratory experiments, researchers at Karolinska Institutet in Sweden demonstrate that ...

What makes pancreatic cancer so aggressive?

April 18, 2017
Pancreatic cancer is one of the most aggressive tumour types because it starts forming metastases early. The cancer itself, however, is usually only discovered late. This leads to a high patient mortality rate. Researchers ...

Gene-regulatory factors shown to improve pancreatic cancer response to chemotherapy

August 1, 2017
Pancreatic cancer is a particularly devastating disease because of the difficulty of identifying it at an early stage, and the difficulty of treating it when discovered at a late stage. Although various treatment options ...

Tumour protein could hold key to pancreatic cancer survival

February 23, 2017
A diagnosis of pancreatic cancer is often a death sentence because current chemotherapies have little impact on the disease.

Scans could help tailor pancreatic cancer treatment

February 12, 2018
Doctors should use a specialised type of scan to help decide if patients with pancreatic cancer may benefit from surgery, according to the National Institute for Health and Care Excellence (NICE).

Potential therapy identified for aggressive breast cancer

January 25, 2018
The European Cancer Stem Cell Research Institute, based with Cardiff University, has repurposed a current cancer therapy, TRAIL, to find a new treatment for advanced cancers that are resistant to anti-hormone therapy.

Recommended for you

'Druggable' cancer target found in pathway regulating organ size

November 20, 2018
It's known that cancer involves unchecked cell growth and that a biological pathway that regulates organ size, known at the Hippo pathway, is also involved in cancer. It's further known that a major player in this pathway, ...

A study suggests that epigenetic treatments could trigger the development of aggressive tumours

November 20, 2018
A study headed by the Institute for Research in Biomedicine (IRB Barcelona) and published in the journal Nature Cell Biology examined whether the opening of chromatin (a complex formed by DNA bound to proteins) is the factor ...

Redefining colorectal cancer subtypes

November 20, 2018
There is a long-standing belief that colorectal cancer (CRC), which causes some 50,000 deaths in the United States each year, can be categorized into distinct molecular subtypes. In a paper published recently in the journal Genome ...

Proposed cancer treatment may boost lung cancer stem cells, study warns

November 20, 2018
Epigenetic therapies—targeting enzymes that alter what genes are turned on or off in a cell—are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant. Researchers at Boston ...

New drug discovery could halt spread of brain cancer

November 19, 2018
The tissues in our bodies largely are made of fluid. It moves around cells and is essential to normal body function.

A molecule for fighting muscular paralysis

November 19, 2018
Myotubular myopathy is a severe genetic disease that leads to muscle paralysis from birth and results in death before two years of age. Although no treatment currently exists, researchers from the University of Geneva (UNIGE), ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.